Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Operating Expenses: 2014-2025

Historic Other Operating Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 2 years, with Sep 2025 value amounting to $453,000.

  • Viridian Therapeutics, Inc.\DE's Other Operating Expenses rose 332.31% to $453,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year decrease of 1.27%. This contributed to the annual value of $69.9 million for FY2020, which is N/A change from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Other Operating Expenses stood at $453,000 for Q3 2025, which was up 332.31% from -$195,000 recorded in Q3 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Other Operating Expenses peaked at $453,000 during Q3 2025, and registered a low of -$195,000 during Q3 2024.
  • Its 2-year average for Other Operating Expenses is $129,000, with a median of $129,000 in 2024.
  • Data for Viridian Therapeutics, Inc.\DE's Other Operating Expenses shows a peak YoY skyrocketed of 332.31% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Viridian Therapeutics, Inc.\DE's Other Operating Expenses stood at -$195,000 in 2024, then skyrocketed by 332.31% to $453,000 in 2025.
  • Its Other Operating Expenses stands at $453,000 for Q3 2025, versus -$195,000 for Q3 2024 and $69.9 million for Q4 2020.